Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Attempts to raise protective immunity to HIV have been notably ineffective. However the conservation of binding of different virus strains to CD4 suggests that the HIV envelope glycoprotein (gp120) should have a conserved site for CD4. Attempts to raise neutralizing anti-idiotypes to CD4 monoclonal antibodies (MoAbs) have generated polyclonal sera which block HIV-induced syncytium formation in vitro but have low titres. Mapping of CD4 epitopes recognized by CD4 MoAbs and gp120 indicates that none of the present CD4 MoAbs bind to exactly the same site as gp120, which may explain the relative lack of success of the anti-idiotype approach to date.


Journal article


J Autoimmun

Publication Date



2 Suppl


243 - 249


Animals, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antigens, Differentiation, T-Lymphocyte, Binding, Competitive, HIV, HIV Antibodies, HIV Antigens, Immunoglobulin Idiotypes, Mice, Receptors, Virus, Viral Vaccines